Cambridge Healthtech Institute Training Seminars offer real-life case studies, problems encountered and solutions applied, and extensive coverage of the basic science underlying each topic. Experienced Training Seminar instructors offer a mix of formal lectures, interactive discussions and activities to help attendees maximize their learning experiences. These immersive trainings will be of value to scientists from industry and academic research groups who are entering new fields – and to those working in supporting roles that will benefit from an in-depth briefing on a specific aspect of the industry.
Monday, Tuesday August 5-6, 2019
Introduction to Cancer Immunotherapy Discovery and Development - Detailed Agenda
This course will cover the recent advances in cancer immunotherapy discovery and development. Immune checkpoint inhibitors and CAR T therapies have recently gained regulatory approval in the US and the EU. TILs- and TCR -based therapies, as well
as cancer vaccines are areas of great promise. Combination therapies are contributing to the clinical progress where single therapies fail. Advances in high throughput sequencing and immunogenomics aid in identifying novel tumor antigens, improving
effector molecules and vaccines, and predicting clinical outcomes.
Dina Schneider, PhD, Associate Director, Translational Research, Lentigen Technology, a Miltenyi Biotec Company
Tuesday, Wednesday August 6-7, 2019
Introduction to Immunology for Drug Discovery Scientists - Detailed Agenda
This 1.5 day seminar will cover the fundamentals of human immunology for an audience of scientists across different backgrounds working in pharmaceutical and biotech organizations in programs related to immunotherapy. The course will cover a historical
perspective, basic mechanisms, fundamental concepts and practical approaches to developing therapeutics and their combinations to modulate the immune system. Additionally, the class will offer perspectives on how immune responses can be monitored
by assessment of biomarkers and modulated through biopharmaceutical intervention. Through group activities, attendees will actively review immunological concepts as well as design functional immunological assays and read-outs.
Masha Fridkis-Hareli, MSc, PhD, Founder and President, ATR, LLC
Tatiana Novobrantseva, PhD, Co-Founder, Chief Scientific Officer, Verseau Therapeutics